This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

ABA Appoints Covington’s Flannery To Federal Judiciary Committee

August 15, 2011

WASHINGTON, DC, August 15, 2011 — Covington & Burling LLP is pleased to announce that Ellen Flannery has been appointed to the American Bar Association Standing Committee on the Federal Judiciary.

Ms. Flannery is co-chair of the firm’s food and drug law practice group. She will serve a three-year term as the Federal Circuit member of the committee.

At the request of the White House, the committee conducts an evaluation of each prospective nominee for the federal district courts, circuit courts of appeal, and the U.S. Supreme Court. The committee has been conducting these evaluations for nearly 60 years.

After the president nominates an individual for the federal court, the committee releases its rating of Well Qualified, Qualified or Not Qualified. The Senate Judiciary Committee uses those ratings to help determine whether to confirm the nominee. The committee is comprised of a chair and 14 circuit members, two in the 9th Circuit and one in each of the other federal circuits.

Ms. Flannery has been active in the ABA leadership for three decades. She is the past chair of the Section of Science & Technology Law and has been a member of the ABA House of Delegates since 1993.

“It is a great privilege to serve on the Standing Committee on the Federal Judiciary,” said Ms. Flannery, who clerked for the U.S. Court of Appeals for the District of Columbia Circuit in 1978-79.

At Covington, Ms. Flannery advises clients on matters relating to regulation of medical devices, pharmaceuticals, and biological products. She helps clients develop strategic plans about the appropriate premarket pathway and development plan for obtaining FDA marketing clearance or approval and advises on postmarketing requirements. She also advises on dispute resolution with FDA, including representing clients in Medical Devices Dispute Resolution Panel proceedings.

Share this article: